Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2014

View Archived Issues

Development of a live-attenuated HIV-1 virus incapable of reactivation

Passive immunization against N-terminally truncated beta-amyloid species with NT4X-167 tested

Enrollment open in phase I study of SM-04755 in colorectal, gastric, hepatic or pancreatic cancer

Celladon in-licenses gene therapy application rights for mSCF for cardiac ischemia treatment

MetaMax initiates phase I/IIa study of MM-D37K

Shire recaps progress of second quarter 2014

Cerecor raises funds to support development of pipeline

Sorrento Therapeutics receives NCI grant for Myc inhibitor

NIBIB award supports Celsion's development of ThermoDox for brain tumors

Implantation of cells secreting NGF proves safe in Alzheimer's disease study

Cadila Healthcare discloses new PARP-1 inhibitors

Celon Pharma describes novel PDE9A inhibitors with procognitive potential

Shionogi patents novel cephems

Researchers present phase II data for ELND-005

Roche synthesizes novel COMT inhibitors

Scientists at OriBase Pharma divulge novel protein kinase inhibitors

FDA grants orphan drug status to palovarotene for FOP

European group designs new agents for viral infections

Ganetespib advances into phase III extension of AML LI-1 study

Pierre Fabre presents novel agents for schizophrenia and other disorders

Anavex Life Sciences secures cGMP manufacturing for ANAVEX 2-73

Sage Therapeutics receives fast track designation for SAGE-547

Kyorin signs license agreement with Merck & Co. for vibegron

First phase I trial of JZP-386 begins

Teva acquires Labrys and enhances migraine portfolio

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...